Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long Road Home: The Continuing Journey of Metastatic Disease.

JCO oncology practice·2026
Same author

Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER<sup>+</sup>HER2<sup>-</sup> breast cancer: a randomized phase 2 trial.

Nature medicine·2026
Same author

Multi-Omic Landscape of Gastrointestinal Stromal Tumors in a Real-World Patient Cohort of 1,427 Cases.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Clinical Utility of Transcriptomic Signatures to Identify Androgen Receptor and Neuroendocrine Signaling in Prostate Cancer.

JCO precision oncology·2026
Same author

Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Palbociclib and endocrine therapy diminish adaptive anti-tumor immunity in early breast cancer: The NeoRHEA phase 2 study.

Nature communications·2025

Related Experiment Video

Updated: Nov 20, 2025

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
08:25

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

11.5K

Liquid biopsy enters the clinic - implementation issues and future challenges.

Michail Ignatiadis1, George W Sledge2, Stefanie S Jeffrey3

  • 1Department of Medical Oncology, Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium. michail.ignatiadis@bordet.be.

Nature Reviews. Clinical Oncology
|January 21, 2021
PubMed
Summary

Liquid biopsy, using circulating tumour DNA (ctDNA), is revolutionizing cancer care, especially for advanced stages. The next step is detecting

More Related Videos

A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications
05:26

A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications

Published on: September 16, 2022

4.3K
Automatic Separation and Collection of Cancer-Related Substances from Clinical Samples
08:49

Automatic Separation and Collection of Cancer-Related Substances from Clinical Samples

Published on: January 13, 2023

2.1K

Related Experiment Videos

Last Updated: Nov 20, 2025

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
08:25

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

11.5K
A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications
05:26

A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications

Published on: September 16, 2022

4.3K
Automatic Separation and Collection of Cancer-Related Substances from Clinical Samples
08:49

Automatic Separation and Collection of Cancer-Related Substances from Clinical Samples

Published on: January 13, 2023

2.1K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Disseminated tumor cells and circulating tumor cells have historically aided cancer research.
  • Advances in detecting circulating tumor DNA (ctDNA) have led to clinical liquid biopsy assays.
  • FDA approvals of ctDNA-based companion diagnostics signify a shift towards widespread clinical use, particularly in advanced cancers.

Purpose of the Study:

  • To discuss the current state and future potential of liquid biopsy in clinical oncology.
  • To introduce the concept of 'ctDNA relapse' for early detection after curative therapy.
  • To identify key challenges and gaps in technology, trial design, and logistics for liquid biopsy integration.

Main Methods:

  • This perspective synthesizes current knowledge and expert opinion on liquid biopsy.
  • It reviews FDA-approved ctDNA assays and their clinical applications.
  • It discusses emerging applications like ctDNA relapse detection, screening, and diagnosis.

Main Results:

  • Liquid biopsy assays, particularly multigene ctDNA tests, are increasingly used as companion diagnostics.
  • The concept of 'ctDNA relapse' offers a new paradigm for monitoring early-stage cancer recurrence.
  • Significant technological, methodological, and logistical hurdles remain for broader implementation.

Conclusions:

  • Liquid biopsy represents a significant advancement in cancer diagnostics and treatment monitoring.
  • Future applications in early-stage disease monitoring and cancer screening hold great promise.
  • Addressing current gaps is crucial for fully integrating liquid biopsy into routine clinical practice.